

Nationwide Compounding Opportunity

Revenue

\$ 8,383,347

Prescriptions

54,940

Revenue Per Script

\$ 153

Gross Margins

61%

Overview

- 2 Pharmacy Locations, separate entities
- Provides Nonsterile, Sterile, Workman's Comp, and Specialty medications
- Servicing patients in 42 states


Employee Breakdown

- 9 Pharmacists
- 14 Pharmacy Technicians
- 4 Other Employees

Financial Highlights

- Combined EBITDA 1.14MM (2021E)
- Gross Profit 3.9MM (2021E)
- Potential Synergy EBITDA 1.86MM

Revenue Breakdown



Opportunities

Combined Synergies



Combining operating expenses and buying power, synergies would be seen immediately



Direct To Consumer

Infrastructure and Licensing nationwide is advantageous to implementing a DTC platform



Accreditations

Adding Accreditations can increase patient access



PCAB for Compounding or URAC for Specialty



Merger

Merging both companies will provide over 700K from baseline EBITDA

